ASTRAZENECA PLC (AZN)
A+
Pipeline Grade
Drug Pipeline (41 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
SELUMETINIB SULFATE
KOSELUGO |
APPROVED | — |
|
ANASTROZOLE
ARIMIDEX |
APPROVED | — |
|
ALBUTEROL SULFATE, BUDESONIDE
AIRSUPRA |
APPROVED | — |
|
BUDESONIDE, FORMOTEROL FUMARATE
SYMBICORT AEROSPHERE |
APPROVED | — |
|
ROSUVASTATIN CALCIUM
CRESTOR |
APPROVED | Acute Coronary Syndrome, Acute Heart Failure, Alzheimer's Disease, Asthma, Atrial Fibrillation, Barrett's Esophagus, Bipolar Episodes, Bladder Cancer, Breast Cancer, Cancer of Head and Neck, Caucasian Patients With EGFR Mutation Positive Advanced NSCLC, Cervical Cancer, Chronic Idiopathic Urticaria, Chronic Kidney Disease, Chronic Obstructive Lung Disease, Chronic Obstructive Pulmonary Disease, CKD Anemia in Stable Dialysis Patients, COVID-19, Cystic Fibrosis, Demographic and Clinical Characteristics for Those Patients, Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan, Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan, Description of the Course of SLE in Patients in the Republic of Kazakhstan, Diabetes, Diabetes Mellitus, Type 2, Diabetic Kidney Disease, Duodenal Ulcer, Dyslipidemia, Dyslipidemia, Renal Insufficiency, Dyslipidemias, Dyspepsia, EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metast |
|
FORMOTEROL FUMARATE, GLYCOPYRROLATE
BEVESPI AEROSPHERE |
APPROVED | — |
|
OSIMERTINIB MESYLATE
TAGRISSO |
APPROVED | — |
|
BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE
SYMBICORT |
APPROVED | — |
|
CAPIVASERTIB
TRUQAP |
APPROVED | — |
|
SELUMETINIB
KOSELUGO |
APPROVED | — |
|
BICALUTAMIDE
CASODEX |
APPROVED | — |
|
SODIUM ZIRCONIUM CYCLOSILICATE
LOKELMA |
APPROVED | — |
|
TICAGRELOR
BRILINTA |
APPROVED | — |
|
ACALABRUTINIB
CALQUENCE |
APPROVED | — |
|
ACALABRUTINIB MALEATE
CALQUENCE |
APPROVED | — |
|
OMEPRAZOLE MAGNESIUM
PRILOSEC OTC |
NDA | — |
|
GEFITINIB
IRESSA |
NDA | — |
|
PRILOCAINE HYDROCHLORIDE
CITANEST |
NDA | — |
|
FELODIPINE
PLENDIL |
NDA | — |
|
EPINEPHRINE BITARTRATE, PRILOCAINE HYDROCHLORIDE
CITANEST FORTE |
NDA | — |
|
ENALAPRIL MALEATE, FELODIPINE
LEXXEL |
NDA | — |
|
OLAPARIB
LYNPARZA |
NDA | — |
|
VITAMIN A
AQUASOL A |
NDA | — |
|
DYCLONINE HYDROCHLORIDE
DYCLONE |
NDA | — |
|
LIDOCAINE, PRILOCAINE
EMLA |
NDA | — |
|
OMEPRAZOLE
PRILOSEC |
NDA | — |
|
BUDESONIDE
PULMICORT |
NDA | — |
|
DEZOCINE
DALGAN |
NDA | — |
|
FUROSEMIDE
FUROSEMIDE |
NDA | — |
|
ETIDOCAINE HYDROCHLORIDE
DURANEST |
NDA | — |
|
EPINEPHRINE, ETIDOCAINE HYDROCHLORIDE
DURANEST |
NDA | — |
|
EPINEPHRINE BITARTRATE, ETIDOCAINE HYDROCHLORIDE
DURANEST |
NDA | — |
|
ISOETHARINE HYDROCHLORIDE
ISOETHARINE HYDROCHLORIDE |
NDA | — |
|
TOCAINIDE HYDROCHLORIDE
TONOCARD |
NDA | — |
|
ESOMEPRAZOLE SODIUM
NEXIUM IV |
NDA | — |
|
DROPERIDOL, FENTANYL CITRATE
FENTANYL CITRATE AND DROPERIDOL |
NDA | — |
|
LIDOCAINE
XYLOCAINE |
NDA | — |
|
RITODRINE HYDROCHLORIDE
YUTOPAR |
NDA | — |
|
DROPERIDOL
DROPERIDOL |
NDA | — |
|
OMEGA-3-CARBOXYLIC ACIDS
EPANOVA |
NDA | — |
|
METAPROTERENOL SULFATE
METAPROTERENOL SULFATE |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06465810 | Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis | OTHER | Recruiting | 1,850 |
| NCT07205666 | The Eplontersen Pregnancy and Lactation Outcomes Study | OTHER | Recruiting | 10 |
| NCT06981169 | PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and A... | OTHER | Recruiting | 1,500 |
| NCT06252753 | Observational Study Protocol: LIVER-R | OTHER | Recruiting | 4,490 |
| NCT07430306 | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve S... | PHASE3 | Recruiting | 245 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.